×


 x 

Shopping cart
John Geigert - The Challenge of CMC Regulatory Compliance for Biopharmaceuticals - 9781493943999 - V9781493943999
Stock image for illustration purposes only - book cover, edition or condition may vary.

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

€ 219.19
FREE Delivery in Ireland
Description for The Challenge of CMC Regulatory Compliance for Biopharmaceuticals Paperback. In its new edition, this book reviews the challenges facing quality assurance and control (QA/QC) in today's biopharmaceutical environment, putting into perspective the need for a graded approach to QA/QC from early clinical trials through market approval. Num Pages: 367 pages, 7 black & white illustrations, 17 colour illustrations, 60 black & white tables, biograph. BIC Classification: MBGR; TDCW. Category: (P) Professional & Vocational. Dimension: 254 x 178. Weight in Grams: 699.
This book highlights the challenges facing quality assurance/quality control (QA/QC) in today's biopharmaceutical environment and presents the strategic importance and value generated by QA/QC for their involvement in control of manufacturing. It will put into perspective the need for a graded approach to QA/QC from early clinical trials through market approval. Since the first edition published in 2004, there have been more than 50 new regulatory guidances released by the Food and Drug Administration (FDA), European Medicines Agency (EMA) and ICH that affect the CMC regulatory compliance of biopharmaceuticals; also the application of biosimilars has been developed in Europe and ... Read more

Product Details

Publisher
Springer-Verlag New York Inc.
Format
Paperback
Publication date
2016
Condition
New
Weight
699g
Number of Pages
338
Place of Publication
New York, United States
ISBN
9781493943999
SKU
V9781493943999
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15

About John Geigert
John Geigert is President of BioPharmaceutical Quality Solutions, which specializes in providing CMC regulatory strategy consulting for the biopharmaceutical and biologic industry. Dr. Geigert has over 35 years of CMC industrial experience and leadership in the biopharmaceutical industry. Dr. Geigert has served on the PDA Board of Directors, co-chaired the PDA Biotech Advisory Board and served as an ... Read more

Reviews for The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Goodreads reviews for The Challenge of CMC Regulatory Compliance for Biopharmaceuticals


Subscribe to our newsletter

News on special offers, signed editions & more!